The early pathophysiology of the disease is not well understood. After the initial acinar cell injury, inflammatory cells migrate into the interstitium by adhering to endothelium and escaping from the microcirculation. The mechanisms by which inflammatory cells adhere to endothelial cells are determined by a variety of mediators or cytokines released at sites of tissue damage. Cytokines hold the key to both the local and the systemic inflammatory response in acute pancreatitis. New therapeutic approaches aim to modulate these pathways.5 6 Acute pancreatitis Whatever the initiating event, the dsease can be regarded as progressing in three phases-that is, a local inflammatory response, a systemic inflammatory response that can result in an organ or multiple organ failure, and finally the intervention of infection by translocation of bacteria from the gut.
Initiation
Recent investigations have established that pancreatitis from whatever cause, disrupts the normal stimulus-secretion coupling within the acinar cell.7 This disruption within the acinar cell leads to an event termed 'co-localisation' in which the digestive and lysosomal enzymes merge resulting in premature activation of proteases. 8 As a result there is a preference for basolateral rather an apical protease secretion and hence release of these enzymes into the pancreatic interstitium. 9 16 Organ dysfunction occurs in one in four patients with acute pancreatitis and 60% of patients who die in the first week of the disease die from pulmonary damage resulting from adult respiratory distress syndrome. 17 Eschericha coli, indicating an endogenous intestinal origin for these bacteria, which probably reach the pancreas via blood, lymph, bile, duodenal chyme, and the transperitoneal route.'9 20 Recent evidence suggests that suppression of the local inflammatory response with anticytokine therapy significantly reduces bacterial contamination.
Cytokine response Inflammatory disorders arise when the response is misdirected to normal tissue and persists for longer than it is needed. The evidence for an amplified cytokine resonse as an important element in the development of complications in acute pancreatitis will be outlined below.
Endotoxin
Is endotoxin the trigger for SIRS in acute pancreatitis? Serum endotoxin assay is difficult. Although endotoxin can be detected in 30-50% of patients with acute pancreatitis and in 90% of non-survivors, it is not prognostic of lethality. Antiendotoxin core antibody can be detected in 85% of patients and in all patients with severe disease, suggesting that at some time during the course of the disease endotoxin exposure occurred. However, in germ free rats unable to mount an endotoxin response, tumour necrosis factor production in acute pancreatitis is the same as in normal rats, suggesting that the cytokine cascade is independent of endotoxin production.21-23 As in sepsis, antiendotoxin treatments are unlikely to be an effective therapy in the early stages of the disease. The proximal cytokine cascade is a more logical target.
Tumour necrosis factor Assay measurements for serum tumour necrosis factor are also problematic, both in terms of sensitivity, ligand binding, and the differentiation of free from bound tumour necrosis factor. Nevertheless serum tumour necrosis factor is detectable in only 10-40% of patients and in 23-45% of non-survivors. In experimental acute pancreatitis tumour necrosis factor exhibits an early peak at two hours after induction of the disease and pre-treatment protocols with anti-tumour necrosis factor antibodies have produced conflicting results in terms of efficacy.2' 24-27 The 'fingerprint' for previous tumour necrosis factor exposure is the measurement of soluble tumour necrosis factor receptors in serum and these can be detected in all patients with mild or severe disease.'4 Present evidence indicates that tumour necrosis factor, which is a predominantly macrophage derived cytokine providing an autocrine and paracrine signal in preference to an endocrine one, is an inappropriate target for anticytokine therapy in acute pancreatitis. PAF is an important mediator in the normal physiological functions of the pancreas gland.37A3 PAF stimulates amylase release from isolated rat pancreatic acini and nanomolar injection of PAF into pancreatic arterioles can induce or aggravate acute pancreatitis in rats and rabbits and potentiate lipopolysaccharide damage. Moreover, in immune complex induced, caerulein induced, and taurocholate induced experimental pancreatitis, PAF is released into the pancreas, ascitic fluid, lung, and blood.
Numerous investigators have used PAF antagonists in experimental acute pancreatitis.37 40-42 4"9 All reported results are positive, although the agents were given in a pretreatment regimen. Overall, PAF antagonists ameliorate the severity of experimental acute pancreatitis by reducing serum amylase, oxidative injury, morphological changes, white cell infiltration, vascular permeability in pancreas and lungs, pulmonary damage, blood, and peritoneal PAF exudative concentrations.
Lexipafant, a computer image analysis generated imidazolyl derivative of the Sp2 nitrogen compounds, is a powerful PAF receptor antagonist having an affinity for the receptor seven times more avid than PAF itself. 33 In the microvascular ischaemia model of acute pancreatitis, this compound is effective in ameliorating the local pancreatic damage when given after induction of the disease.50 Lexipafant has subsequently undergone a successful randomised double blind Phase II clinical trial in human acute pancreatitis. 13 In this study 83 patients were randomised to receive lexipafant 60 mg intraveneously for three days or placebo. Clinical progression was assessed by daily APACHE II scores and organ failure scores and the magnitude of the inflammatory response was assessed by serial measurements of interleukin 8, interleukin 6, E-selectin, PMN elastase, and C reactive protein. Twenty nine patients had severe disease with an APACHE II score of 8 or greater. Lexipafant treatment resulted in a significant reduction in organ failure: seven of 12 patients had resolution of an organ failure while 11 patients remained with an organ failure in the placebo group. In addition there was a significant reduction in the total organ failure scores at the end of medication and lexipafant reduced serum IL 8 (p<004) and reduced IL 6 and E selectin. These encouraging results of a downregulation of the SIRS associated with the disease has resulted in the initiation of a Phase III study in patients with severe acute pancreatitis, the results of which are awaited.
Interleukin 1 (IL 1) IL 1 shares many of the properties of tumour necrosis factor, being regarded as an early inducer of many of the systemic and acute phase responses to injury.5' IL 1 is difficult to measure in serum and its natural antagonist, interleukin 1 receptor antagonist (IL Ira) may more accurately reflect the degree to which IL 1 stimulation has occurred.52 After major trauma IL lra levels precede rises in IL 6 indicating that the IL 1 Conclusions Although a number of treatments are currently available to treat various aspects of pancreatic inflammation, they have failed to make a significant impact on the disease overall. Antioxidant therapy for instance can reduce symptom scores and pain scores in recurrent pancreatitis.6' Imipenem and cefuroxime antibiotics can reduce the number of septic complications and improve mortality in a subgroup of patients with acute necrotising pancreatitis.62 63 What is needed, however, is an effective treatment during the early course of the disease that prevents SIRS and organ failure, and which may also ameliorate necrosis and prevent subsequent infection in the gland. Because of our rapidly increasing knowledge of the mechanisms of the systemic inflammatory response and multiple organ failure in acute pancreatitis, a number of new therapeutic approaches to the disease are in various stages of development.64 However, it is vital that clinical trials are not started before adequate laboratory and experimental data are available to fully characterise cytokine networks and identify the dominant mediators in acute pancreatitis. Cytokine inhibitors must aim to downregulate the cascade or ripple effect before the tidal pancreatitis. 
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